Circumvent the Tariff challenges with an agile supply chain Consulting
Supply Chain Ecosystem Analysis now part of DBMR Reports
Global Solid Tumors Market
Market Size in USD Billion
CAGR :
%
USD
362.21 Billion
USD
1,557.42 Billion
2024
2032
Forecast Period
2025 –2032
Market Size(Base Year)
USD
362.21 Billion
Market Size (Forecast Year)
USD
1,557.42 Billion
CAGR
20.00
%
Major Markets Players
F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi
Pfizer Inc.
Global Solid Tumors Market Segmentation, By Site of Origin (Prostrate Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Others), Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032
Solid Tumors Market Analysis
Solid tumors are created by the accumulation of aberrant tissues that do not contain any liquid or cyst in the case of cancer. There are two types of solid tumors: benign and malignant. The treatment of solid tumors is difficult, and it necessitates coordinated actions by a variety of healthcare professionals, including surgeons, radiologists, radiation specialists, oncologists, and others. As a result, chemotherapy, radiation, and/or surgery are used to treat the majority of solid tumors.
Solid Tumors Market Size
Global solid tumors market size was valued at USD 362.21 billion in 2024 and is projected to reach USD 1557.42 billion by 2032, with a CAGR of 20.00% during the forecast period of 2025 to 2032.
Report Scope and Market Segmentation
Attributes
Solid Tumors Key Market Insights
Segmentation
By Site of Origin: Prostrate Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Others
By Therapy Type: Chemotherapy, Immunotherapy, Targeted Therapy
By Route of Administration: Oral, Parenteral, Others
By End User: Hospitals, Specialty Clinics, Homecare, Others
By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others
Countries Covered
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Key Market Players
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Hikma Pharmaceuticals PLC (U.K.), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), Boehringer Ingelheim International GmbH. (Germany), Dr. Reddy’s Laboratories Ltd. (India), Gilead Sciences, Inc. (U.S.), Amgen Inc. (U.S.), Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Lupin (India), Allergan (Ireland)
Market Opportunities
Increase in the number of research and development activities
Rising investment for the development of advanced technologies
Solid Tumors Market Definition
Solid tumors are heterotypic collections of a variety of cell types, including cancer cells, cancer stem cells, connective-tissue cells, and immune cells. For malignant solid tumors, surgery is currently the most appropriate therapeutic choice. Chemotherapy is usually used with other solid tumor treatments such as surgery and radiation. Solid tumor therapies are pharmaceuticals used to treat tumors including lung cancer, breast cancer, prostate cancer, colorectal cancer, cervical cancer, and others. Solid tumor therapeutics are continuing to lead the way in oncology treatments as an effective anti-cancer therapy in the global oncology therapeutics market.
Solid Tumors Market Dynamics
Drivers
Increasing prevalence of different forms of metastatic cancers
The rising prevalence of different forms of metastatic cancer is estimated to enhance the market's growth. In 2012, the World Health Organization (WHO) estimated that 8.2 million people died worldwide as a result of various types of malignancies. Lung, colorectal, breast, and liver cancers were among the most common cancers, with lung, colorectal, and breast cancers being the most common. Brain tumors (medulloblastoma and glioma) and neuroblastoma are the most frequent solid tumors; rhabdomyosarcoma and osteosarcoma are less common solid cancers.
Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of solid tumors market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising initiatives by public and private organizations to spread awareness and growing demand for highly effective chemotherapeutic agents will expand the solid tumors market. Additionally, the sedentary lifestyle of people and increasing incidences of several cases of solid tumors will result in the expansion of solid tumors market. The rising level of disposable income and surging geriatric population are the major factors anticipated to flourish the market’s growth rate during the forecast period of 2025-2032.
Opportunities
Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the solid tumors market growth.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for solid tumors market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the solid tumors market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2025-2032.
This solid tumors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the solid tumors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Solid tumors market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Solid Tumors Market Scope
The solid tumors market is segmented on the basis of site of origin, therapy type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
The solid tumors market is analyzed and market size insights and trends are provided by country, site of origin, therapy type, route of administration, end-users and distribution channel as referenced above.
The countries covered in the solid tumors market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the solid tumors market because of the rising prevalence of solid tumors and technological advancement in the treatment in this region. Additionally, rising healthcare expenditure and the presence of major key players will further propel the market’s growth rate.
Asia-Pacific are expected to grow during the forecast period of 2025-2032 due to the increasing number of geriatric population and surging level of disposable income in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Solid Tumors Market Share
The solid tumors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to solid tumors market.
Solid Tumors Market Leaders Operating in the Market Are:
F. Hoffmann-La Roche Ltd. (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd. (Ireland)
Sanofi (France)
Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
Merck & Co., Inc. (U.S.)
Allergan (Ireland)
AstraZeneca (U.K.)
Johnson & Johnson Private Limited (U.S.)
Hikma Pharmaceuticals PLC (U.K.)
Bristol-Myers Squibb Company (U.S.)
Bayer AG (Germany)
Boehringer Ingelheim International GmbH. (Germany)
Dr. Reddy’s Laboratories Ltd. (India)
Gilead Sciences, Inc. (U.S.)
Amgen Inc. (U.S.)
Eli Lilly and Company (U.S.)
AbbVie Inc. (U.S.)
Lupin (India)
Allergan (Ireland)
Latest Developments in Solid Tumors Market
In May 2021, Amgen announced the U.S. Food and Drug Administration (FDA) approval for LUMAKRAS (sotorasib) for treating adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. LUMAKRAS was given priority approval due to its high overall response rate (ORR) and short response time. Continued approval for this indication could be conditional on a confirmatory trial demonstrating and documenting clinical trials
SKU-53500
Get online access to the report on the World's First Market Intelligence Cloud
Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
Claudio Rondena
Group Business Development & Strategic Marketing Director, C.O.C Farmaceutici SRL
"This morning we were involved in the first part, the data presentation of MKT analysis, selected abstract from your work. The board team was really impressed and very appreciated, as well."
David Manning - Thermo Fisher Scientific
Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice.
Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough.
Your work is much appreciated.
Manager - Market Analytics,
Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Business Development Manager,
(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Business Intelligence and Analytics,
Ipsen Biopharm Limited
We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.
Competition Analyst,
Basler Web
I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.
Marketing Director,
Buhler Group
It was indeed a good experience, would definitely recommend and come back for future prospects.
COO,
A global leader providing Drug Delivery Services
DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.
Marketing Director,
Philips Healthcare
The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.
Product manager,
Fujifilms
Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.
Investor relations,
GE Healthcare
Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.
Market Analyst,
Medincell
We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.
Andrew - Senior Global Marketing Manager,
Medtronic (US)
I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.
Amarildo - Manager, Global Strategic Alignment
MasterCard
We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.
Tor Hammer
Green Nexus LLc
Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects
I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying.
Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.
Yuki Kopyl (Asian Business Development Department)
UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)
Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future